Bayer logo
US MEDICAL AFFAIRS

Publications

Publications

Home/Publications

We invite you to explore Bayer-supported publications. This library is not intended to serve as a comprehensive repository of all publications. Publications not supported by Bayer are not included. Access to the full text of publications may depend on journal access rights.

To help narrow down your search, choose the relevant tags and click Apply. Selecting multiple tags will narrow your results.

Last updated September 16, 2025.

Types of Enhancements Available

Audio Icon
Audio
Infographic Icon
Infographic
Plain language summary icon
Plain Language Summary
Video icon
Video
Digital enhancements icon
Other

To help narrow down your search, select the relevant filters from the dropdowns and Click Apply

Hold down Ctrl key on keyboard to select multiple years

Total available publications: 339    

Filtered results: 14

Complete response to larotrectinib treatment in a patient with papillary thyroid cancer harboring an ETV6-NTRK3 gene fusion

Pitoia F, et al. Clin Case Rep. 2021;9(4):1905-1912.

Pitoia F,
READ
EMAIL

Multi-kinase Inhibitors for the Treatment of Asymptomatic Radioactive Iodine-Refractory Differentiated Thyroid Cancer: Global, Non-Interventional Study (RIFTOS MKI)

Brose M, et al. Thyroid. 2022;32(9):1059-1068.

Brose M,
READ
EMAIL

Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma

Waguespack SG, et al. Eur J Endo. 2022;186(6):631-643.

Waguespack SG,
READ
EMAIL

Systematic population-based identification of NTRK and RET fusion-positive thyroid cancers

Eszlinger M, et al. Eur Thyroid J. 2022; 11(1): e210061.

Eszlinger M,
READ
EMAIL

The potential long-term comparative effectiveness of larotrectinib vs standard of care for treatment of metastatic TRK fusion thyroid cancer, colorectal cancer, and soft tissue sarcoma

Suh K, et al. J Manag Care Spec Pharm. 2022;28(6):622-630.

Suh K,
READ
EMAIL

Immunohistochemistry and Next-Generation Sequencing for NTRK Fusion detection in Differentiated Thyroid Cancer of Children, Adolescents and Young Adults

Telles AC, et al. Neuro Oncol. 2024;20:e-20240456.

Telles AC,
READ
EMAIL

Neurotrophic-tyrosine receptor kinase gene fusion in papillary thyroid cancer: A clinicogenomic biobank and record linkage study from Finland

Zhang W, et al. Oncotarget. 2024;15: 106-116.

Zhang W,
READ
EMAIL

Real-world practice patterns and outcomes for RAI-refractory differentiated thyroid cancer

Gianoukakis AG, et al. Eur Thyroid J. 2024;13(1):e230039.

Gianoukakis AG,
READ
EMAIL

Timing of multikinase inhibitor initiation in differentiated thyroid cancer

Brose MS, et al. Endocr Relat Cancer. 2017;24(5):237-242.

Brose MS,
READ
EMAIL

Body composition in patients with radioactive iodine-refractory, advanced differentiated thyroid cancer treated with sorafenib or placebo: a retrospective analysis of the phase III DECISION trial

Huillard O, et al. Thyroid. 2019;29(12):1820-1827.

Huillard O,
READ
EMAIL
Bayer logo

You are encouraged to report side effects or quality complaints of products to the FDA by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088. For Bayer products, you can report these directly to Bayer by clicking here.

 

This site provides access to balanced and evidence-based medical information related to our therapeutic areas of focus and is intended to serve as a medical resource for US HCPs. This may include investigational compounds or investigational new uses of FDA-approved Bayer products. The information provided is not intended to be promotional or provide medical advice. Please refer to the full Prescribing Information for approved indications, contraindications, warnings and precautions, and adverse events.

 

© 2026 Bayer. Bayer and the Bayer Cross are registered trademarks of Bayer.

Site last updated 02/2026

Follow Us

Twitter (X) icon Twitter (X) icon
YouTube icon YouTube icon
LinkedIn icon LinkedIn icon
US Medical Affairs QR Code